FOXO4-DRI: the senolytic peptide, the mouse data and the missing human evidence

Cells that have been damaged past repair often do not die. They enter a state called senescence: they stop dividing, they stay alive, and they secrete a mixture of inflammatory signals known as the senescence-associated secretory phenotype, or SASP. Senescent cells accumulate with age and after chemotherapy, and clearing them genetically in mice delays several features of ageing. The question the FOXO4 work set out to answer is why senescent cells refuse to die, so that a drug could push them over the edge.

In 2017 a team at Erasmus University Medical Center in Rotterdam, led by Marjolein Baar and Peter de Keizer, identified the transcription factor FOXO4 as the pivot. In senescent cells FOXO4 holds p53 in the nucleus, and p53 held there cannot do the job that would otherwise trigger the cell’s own death programme. They designed a peptide to get in the way of that interaction. Under conditions where it was tolerated in living mice, this peptide neutralised doxorubicin chemotoxicity, and it restored fitness, fur density and kidney function in both fast-ageing XpdTTD/TTD mice and naturally aged mice ^[1].

The DRI in the name stands for D-retro-inverso. The sequence is built from D-amino acids in reverse order, a trick that produces a molecule with a similar shape to the natural L-peptide but one that protein-chopping enzymes struggle to recognise, so it survives longer. A cationic cell-penetrating leader sequence carries it into cells. Later structural work confirmed that both parts matter: solution NMR showed that FOXO4-DRI binds the disordered transactivation domain of p53 and that both the FOXO4-derived region and the cell-permeability peptide contribute to the interaction ^[2].

You will see it written as FOXO4-DRI, FOXO4 DRI, FOX04-DRI with a zero instead of an O, and occasionally as proxofim. They all refer to the same research peptide. Searches for FOXO4-DRI peptide and for FOXO4-DRI senolytic activity land on the same compound. Our guide to what research peptides are covers what the research-use label on the vial does and does not mean. It is often discussed alongside other longevity-branded compounds sold by the same stores, such as epitalon and NAD+, though none of those works by killing senescent cells.

The mechanism is an interruption, not an activation. FOXO4-DRI is a decoy: it competes for the surface of p53 that FOXO4 would otherwise occupy ^{[1] [2]}. When that grip is broken in a senescent cell, p53 is excluded from the nucleus and the cell undergoes intrinsic apoptosis. Cells that are not senescent do not depend on this interaction in the same way, which is the basis of the claimed selectivity ^[1].

The 2025 structural study added a detail with practical implications: phosphorylation of p53 increases its affinity for both FOXO4 and FOXO4-DRI ^[2]. A keloid fibroblast study made the same point from the cell-biology side, reporting that FOXO4-DRI triggered apoptosis in senescent fibroblasts by promoting nuclear exclusion of p53 phosphorylated at serine 15 ^[3]. In other words, the peptide works best where p53 is already under stress signalling, which is one reason its effects are so context-dependent.

Because FOXO4-DRI is a senolytic rather than a hormone or a receptor agonist, its effects depend entirely on how many senescent cells are present and on what those cells were doing. This is not an abstract caveat. It is the reason the same compound improves one tissue and damages another in the published literature.

All of the FOXO4-DRI benefits reported so far are from cell and animal experiments. The founding study reported restored fitness, fur density and renal function in aged and fast-ageing mice, and protection against doxorubicin-induced chemotoxicity ^[1]. Everything since has tested the same idea in a particular tissue.

Testes and testosterone: a 2020 study found FOXO4 concentrated in human Leydig cells, and that its movement into the nucleus in older men tracked reduced testosterone synthesis. In naturally aged mice, FOXO4-DRI selectively killed senescent Leydig cells, improved the testicular environment and eased age-related testosterone insufficiency ^[4]. A follow-up in 2024 from the same group reported improved sperm quality and spermatogenesis in aged mice, attributed to less SASP secretion from Leydig cells ^[5]. This is the source of most FOXO4-DRI testosterone claims online; it is mouse data.

Cartilage: in cells expanded for autologous chondrocyte implantation, FOXO4-DRI removed more than half of the cells at a high population doubling level while leaving minimally expanded cells largely untouched, which is a clean demonstration of selectivity in human cells in the dish ^[6].

Fibrosis: FOXO4-DRI reduced extracellular matrix production by fibroblasts and improved bleomycin-induced pulmonary fibrosis in mice ^[7], and a related FOXO4 peptide targeting myofibroblasts improved the same model through extracellular matrix receptor signalling ^[8]. Scarring: in keloid tissue, the peptide killed senescent fibroblasts ^[3]. Blood vessels: a 2025 study reported that FOXO4-DRI regulated endothelial cell senescence through the p53 pathway ^[9].

A 2026 pharmacological review of retro-inverso senolytics targeting the FOXO4-p53 axis frames the whole area as a strategy for brain ageing and cognitive decline that remains at the preclinical stage ^[10]. No paper we found reports a FOXO4-DRI human study of any kind.

This needs stating plainly, because FOXO4-DRI is sold and discussed as though it were an anti-ageing treatment. There is no published clinical trial of FOXO4-DRI. There is no registered trial of FOXO4-DRI on ClinicalTrials.gov. No regulator has reviewed it. The only human material that has been exposed to it in published work is cells in a dish: expanded chondrocytes ^[6], keloid fibroblasts ^[3], endothelial cells ^[9] and, in the structural study, purified proteins ^[2].

A company, Cleara Biotech, was founded in Utrecht on this science, and the authors of the structural paper declare shares in it and patents covering compounds that bind p53 and block the FOXO4 interaction ^[2]. Commercial development is not the same thing as clinical evidence. As of September 2026 we are not aware of any FOXO4-DRI clinical trial results in the public domain.

Anyone reading dosing protocols online should keep that in mind: those protocols are not derived from human research, because no human research exists. For general background on how to read the evidence behind a peptide, see our guides on third-party peptide testing and how to spot a fake peptide supplier.

A 2023 study in Circulation is the most important counterweight to the anti-ageing framing, and it is rarely mentioned in marketing material. The researchers found abundant senescent cells in the lungs of patients with pulmonary arterial hypertension and in mouse models. They then removed those cells by several independent methods: a suicide gene, the senolytic drug ABT263, and FOXO4-DRI. Eliminating the senescent cells raised right ventricular systolic pressure and the hypertrophy index, increased vessel remodelling and sharply reduced the number of pulmonary endothelial cells. In rats given monocrotaline, ABT263 slightly reduced pulmonary hypertension at one week and clearly worsened it at three weeks ^[11].

The authors’ conclusion is that eliminating senescent pulmonary endothelial cells may worsen pulmonary haemodynamics, and that this should be considered in any strategy aimed at controlling senescence ^[11]. Senescent cells are not simply debris. Some of them are doing load-bearing work, and a senolytic cannot tell the difference.

A second caution comes from the cancer side. The same peptide that pushes senescent cells into apoptosis by displacing p53 is, structurally, a p53 inhibitor, and the patents arising from the structural work describe compounds that bind and inhibit p53 explicitly as a route to treating cancers ^[2]. p53 is the most important tumour-suppressor protein in the human genome. Interfering with it outside a controlled setting is not a small thing to do, and nobody has measured what repeated exposure does to cancer risk in a living human.

There is no honest answer for people, because no one has measured it in people. In the founding mouse experiments, effects on fur density, fitness and kidney function were assessed over weeks of intermittent dosing ^[1], and the Leydig cell work in aged mice likewise ran over weeks ^{[4] [5]}. Cell experiments show senescent cells dying within days of exposure ^[6].

Senolytics are usually given in short intermittent courses rather than continuously, on the logic that a senescent cell killed today does not need to be killed again tomorrow. That logic comes from mouse protocols, and no clinical schedule for FOXO4-DRI exists.

What follows describes published animal and cell experiments. These are not recommendations, and no dose of FOXO4-DRI has been tested for safety in a human being. The 2017 Cell study administered the peptide to mice intraperitoneally in intermittent courses, choosing conditions under which it was tolerated in vivo, and reported the recovery of fur, fitness and renal markers over the following weeks ^[1]. Subsequent mouse studies in testes, lung and skin used similar intermittent intraperitoneal schedules ^{[4] [5] [7]}. Cell studies typically expose cultures to micromolar concentrations for a short window and then count surviving senescent cells ^[6].

Milligram-per-kilogram figures from mouse papers cannot be carried across to people by simple arithmetic, and the peptide is large, at around 5358 g/mol, which matters when a vial is labelled in milligrams. If you are working out what a stated vial content means as a concentration, our peptide calculator and the FOXO4-DRI calculator page handle the conversion, but a correct calculation of an unvalidated dose is still an unvalidated dose.

Published animal work used injection, most often intraperitoneal ^{[1] [4] [7]}. Research suppliers sell FOXO4-DRI as a lyophilised powder for reconstitution. There is no published study of oral, nasal or topical FOXO4-DRI, and no published pharmacokinetic data in any species that would let anyone reason about absorption, distribution or clearance. The D-amino acid retro-inverso design is intended to resist enzymatic breakdown ^[2], which affects how long it survives but tells you nothing about where it goes.

No human safety data exist. Nothing here should be read as a description of what FOXO4-DRI does in a person, because that has never been measured. What the animal literature offers is two kinds of signal.

The reassuring signal is the selectivity result: in expanded human chondrocytes the peptide killed more than half the cells at high population doubling but did not significantly affect minimally expanded cells ^[6], and the founding study reported that mice tolerated intermittent dosing without losing the benefit ^[1].

The alarming signal is the Circulation study, in which clearing senescent pulmonary endothelial cells with FOXO4-DRI or another senolytic worsened pulmonary haemodynamics and destroyed endothelial cells ^[11]. Add to that the p53 question described above ^[2], and the honest summary is that FOXO4-DRI side effects in humans are unknown, that the mechanism has a plausible route to serious harm, and that at least one peer-reviewed study has already found harm in an animal model. Nothing is known about its effect in pregnancy, on fertility in humans, on cancer risk or over repeated courses.

FOXO4-DRI is not an approved medicine anywhere we are aware of, and it has no marketing authorisation, no orphan designation and no registered clinical trial. It is sold as a research chemical. Where that leaves a buyer depends on the country: see our legal status overview and the country pages for the UK, the US and Australia. Enforcement against research-use framing has been tightening, as our report on the FDA advisory committee meeting on compounded peptides sets out.

We have not confirmed its status on the WADA Prohibited List. It has no plausible performance-enhancing rationale, and we found no anti-doping method paper covering it.

FOXO4-DRI is supplied as a freeze-dried powder. Peptides are generally stored cold, dry and away from light, and reconstituted solutions are refrigerated and used within a limited period. See how to store peptides and our guide to bacteriostatic water. A 46-residue peptide is at the awkward end of what solid-phase synthesis handles well, so batch-to-batch variation is more likely than with a short peptide.

Two things make purity unusually important here. The peptide is long, which means truncated and deletion sequences are a realistic contaminant, and it is built entirely from D-amino acids in reverse order, which a supplier can get wrong in a way that ordinary mass checking will not catch, since a D-amino acid and its L-form weigh the same. A certificate of analysis showing a mass near 5358 g/mol is necessary but not sufficient.

Compare FOXO4-DRI prices across the suppliers we track, including the UK, the US and Europe. Our guides to reading a peptide COA and peptide prices explained cover what the paperwork and the price should tell you, and the stores that publish independent results are listed under third-party tested suppliers. FOXO4-DRI is expensive to make, so an unusually cheap listing deserves more scepticism than usual, not less.